Abcam, ab314456, Anti-FAP antibody [RM1080]

Size: 20µL / 100µL / 1mL
Anti-FAP antibody [RM1080] (ab314456) is a rabbit recombinant multiclonal antibody detecting FAP in Western Blot, IHC-P, ICC/IF . Suitable for Human . - Biophysical QC for unrivalled batch-batch consistency
Key facts
Host species:Rabbit,
Clonality:Multiclonal,
Clone number:RM1080,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:ICC/IF, IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
What is this antibody validated in?
Anti-FAP antibody [RM1080] (ab314456) is a rabbit recombinant recombinant multiclonal antibody and is validated for use in Western Blot (WB), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human samples.
What is the molecular weight of FAP?
Anti-FAP [RM1080] (ab314456) specifically detects a band for FAP (UniProt: Q12884) at a molecular weight of 88kDa.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl.
Discover our selection of trial-size antibodies
Other related products
We have a range of other formats of antibody clone [RM1080] also available for your convenience: ab314456, Carrier free -
ab314457
What are recombinant multiclonals?
Recombinant multiclonals are a mixture of recombinant antibodies co-expressed from a library of heavy and light chains. They offer several advantages including:
- The sensitivity of polyclonal antibodies by recognising multiple epitopes
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
View our range of
recombinant multiclonal antibodies
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
FAP also known as fibroblast activation protein alpha or seprase is a serine protease with a mass of approximately 97 kDa. It is largely expressed in embryonic tissues certain carcinomas and tissue remodeling sites. FAP acts mechanistically by exhibiting dipeptidyl peptidase and endopeptidase activities breaking down peptide chains. Cellular membrane-bound FAP localizes mainly on reactive stromal fibroblasts not normal tissues making it an interesting target for research.
Biological function summary
FAP plays a role in tissue remodeling and wound healing influencing the microenvironment of tumors and fibrotic tissues. It contributes to extracellular matrix degradation participating in the complex network of proteases. FAP is not a standalone unit but part of a larger complex that interacts with other proteases helping in cell migration and invasion. As a result its activity impacts processes like inflammation and carcinogenesis.
Pathways
FAP participates in processes related to tissue repair and cancer progression. Significant pathways include the degradation of the extracellular matrix and the PI3K/AKT signaling. It functions alongside proteins like DPP4 another dipeptidyl peptidase in these pathways. The matrix breakdown is central to cancer metastasis and wound healing enhancing our understanding of FAP's role in larger biological contexts.
FAP has links with cancer and fibrosis. Its expression correlates with aggressive tumors and poor prognosis in cancers such as breast and ovarian. In fibrotic diseases like pulmonary and liver fibrosis it contributes to excessive matrix deposition and tissue stiffening. FAP's involvement alongside collagenases in these disorders makes it a target of potential therapeutic interest.